107 related articles for article (PubMed ID: 23225780)
1. N-cyano sulfoximines: COX inhibition, anticancer activity, cellular toxicity, and mutagenicity.
Park SJ; Baars H; Mersmann S; Buschmann H; Baron JM; Amann PM; Czaja K; Hollert H; Bluhm K; Redelstein R; Bolm C
ChemMedChem; 2013 Feb; 8(2):217-20. PubMed ID: 23225780
[TBL] [Abstract][Full Text] [Related]
2. In vitro antiproliferative activity against human colon cancer cell lines of representative 4-thiazolidinones. Part I.
Ottanà R; Carotti S; Maccari R; Landini I; Chiricosta G; Caciagli B; Vigorita MG; Mini E
Bioorg Med Chem Lett; 2005 Sep; 15(17):3930-3. PubMed ID: 15993594
[TBL] [Abstract][Full Text] [Related]
3. Covalent modification of cyclooxygenase-2 (COX-2) by 2-acetoxyphenyl alkyl sulfides, a new class of selective COX-2 inactivators.
Kalgutkar AS; Kozak KR; Crews BC; Hochgesang GP; Marnett LJ
J Med Chem; 1998 Nov; 41(24):4800-18. PubMed ID: 9822550
[TBL] [Abstract][Full Text] [Related]
4. Design, synthesis and biological evaluation of novel diphenylthiazole-based cyclooxygenase inhibitors as potential anticancer agents.
Abdelazeem AH; Gouda AM; Omar HA; Tolba MF
Bioorg Chem; 2014 Dec; 57():132-141. PubMed ID: 25462989
[TBL] [Abstract][Full Text] [Related]
5. Celecoxib potentiates the anticancer effect of cisplatin on vulvar cancer cells independently of cyclooxygenase.
Kim SH; Kim SH; Song YC; Song YS
Ann N Y Acad Sci; 2009 Aug; 1171():635-41. PubMed ID: 19723114
[TBL] [Abstract][Full Text] [Related]
6. Effect of cyclooxygenase-2 (COX-2) inhibitors on prostate cancer cell proliferation.
Srinath P; Rao PN; Knaus EE; Suresh MR
Anticancer Res; 2003; 23(5A):3923-8. PubMed ID: 14666698
[TBL] [Abstract][Full Text] [Related]
7. Antitumor-active cobalt-alkyne complexes derived from acetylsalicylic acid: studies on the mode of drug action.
Ott I; Schmidt K; Kircher B; Schumacher P; Wiglenda T; Gust R
J Med Chem; 2005 Jan; 48(2):622-9. PubMed ID: 15658875
[TBL] [Abstract][Full Text] [Related]
8. Synthesis, structure-activity relationships, and in vivo evaluations of substituted di-tert-butylphenols as a novel class of potent, selective, and orally active cyclooxygenase-2 inhibitors. 2. 1,3,4- and 1,2,4-thiadiazole series.
Song Y; Connor DT; Sercel AD; Sorenson RJ; Doubleday R; Unangst PC; Roth BD; Beylin VG; Gilbertsen RB; Chan K; Schrier DJ; Guglietta A; Bornemeier DA; Dyer RD
J Med Chem; 1999 Apr; 42(7):1161-9. PubMed ID: 10197960
[TBL] [Abstract][Full Text] [Related]
9. The effect of selective cyclooxygenase inhibitors on intestinal epithelial cell mitogenesis.
Erickson BA; Longo WE; Panesar N; Mazuski JE; Kaminski DL
J Surg Res; 1999 Jan; 81(1):101-7. PubMed ID: 9889067
[TBL] [Abstract][Full Text] [Related]
10. Synthesis, structure-activity relationships, and in vivo evaluations of substituted di-tert-butylphenols as a novel class of potent, selective, and orally active cyclooxygenase-2 inhibitors. 1. Thiazolone and oxazolone series.
Song Y; Connor DT; Doubleday R; Sorenson RJ; Sercel AD; Unangst PC; Roth BD; Gilbertsen RB; Chan K; Schrier DJ; Guglietta A; Bornemeier DA; Dyer RD
J Med Chem; 1999 Apr; 42(7):1151-60. PubMed ID: 10197959
[TBL] [Abstract][Full Text] [Related]
11. Combination of cyclooxygenase-2 inhibitors and oxaliplatin increases the growth inhibition and death in human colon cancer cells.
Lin J; Hsiao PW; Chiu TH; Chao JI
Biochem Pharmacol; 2005 Sep; 70(5):658-67. PubMed ID: 16004971
[TBL] [Abstract][Full Text] [Related]
12. NOSH-aspirin (NBS-1120), a novel nitric oxide- and hydrogen sulfide-releasing hybrid is a potent inhibitor of colon cancer cell growth in vitro and in a xenograft mouse model.
Chattopadhyay M; Kodela R; Olson KR; Kashfi K
Biochem Biophys Res Commun; 2012 Mar; 419(3):523-8. PubMed ID: 22366248
[TBL] [Abstract][Full Text] [Related]
13. Combination of a selective cyclooxygenase-2 inhibitor with epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 and protein kinase A antisense causes cooperative antitumor and antiangiogenic effect.
Tortora G; Caputo R; Damiano V; Melisi D; Bianco R; Fontanini G; Veneziani BM; De Placido S; Bianco AR; Ciardiello F
Clin Cancer Res; 2003 Apr; 9(4):1566-72. PubMed ID: 12684433
[TBL] [Abstract][Full Text] [Related]
14. Positional isomers of aspirin are equally potent in inhibiting colon cancer cell growth: differences in mode of cyclooxygenase inhibition.
Kodela R; Chattopadhyay M; Goswami S; Gan ZY; Rao PP; Nia KV; Velázquez-Martínez CA; Kashfi K
J Pharmacol Exp Ther; 2013 Apr; 345(1):85-94. PubMed ID: 23349335
[TBL] [Abstract][Full Text] [Related]
15. Expression of cyclooxygenase-2 (COX-2) in hepatocellular carcinoma and growth inhibition of hepatoma cell lines by a COX-2 inhibitor, NS-398.
Bae SH; Jung ES; Park YM; Kim BS; Kim BK; Kim DG; Ryu WS
Clin Cancer Res; 2001 May; 7(5):1410-8. PubMed ID: 11350912
[TBL] [Abstract][Full Text] [Related]
16. Celecoxib and curcumin synergistically inhibit the growth of colorectal cancer cells.
Lev-Ari S; Strier L; Kazanov D; Madar-Shapiro L; Dvory-Sobol H; Pinchuk I; Marian B; Lichtenberg D; Arber N
Clin Cancer Res; 2005 Sep; 11(18):6738-44. PubMed ID: 16166455
[TBL] [Abstract][Full Text] [Related]
17. Celecoxib exhibits the greatest potency amongst cyclooxygenase (COX) inhibitors for growth inhibition of COX-2-negative hematopoietic and epithelial cell lines.
Waskewich C; Blumenthal RD; Li H; Stein R; Goldenberg DM; Burton J
Cancer Res; 2002 Apr; 62(7):2029-33. PubMed ID: 11929821
[TBL] [Abstract][Full Text] [Related]
18. [Cyclopentadienyl]metalcarbonyl complexes of acetylsalicylic acid as neo-anticancer agents.
Rubner G; Bensdorf K; Wellner A; Bergemann S; Ott I; Gust R
Eur J Med Chem; 2010 Nov; 45(11):5157-63. PubMed ID: 20828891
[TBL] [Abstract][Full Text] [Related]
19. Blockade of cyclooxygenase-2 inhibits proliferation and induces apoptosis in human pancreatic cancer cells.
Ding XZ; Tong WG; Adrian TE
Anticancer Res; 2000; 20(4):2625-31. PubMed ID: 10953335
[TBL] [Abstract][Full Text] [Related]
20. Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX-2 inhibitor.
Riendeau D; Percival MD; Boyce S; Brideau C; Charleson S; Cromlish W; Ethier D; Evans J; Falgueyret JP; Ford-Hutchinson AW; Gordon R; Greig G; Gresser M; Guay J; Kargman S; Léger S; Mancini JA; O'Neill G; Ouellet M; Rodger IW; Thérien M; Wang Z; Webb JK; Wong E; Chan CC
Br J Pharmacol; 1997 May; 121(1):105-17. PubMed ID: 9146894
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
